Novavax saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 93.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History shows that the best-performing stocks often have an RS Rating of over 80 at the beginning of a new run.
How To Use Stock Charts To Stay Profitable And Protected
While Novavax is not near an ideal buy zone right now, see if it goes on to form and break out of a proper consolidation.
Novavax reported 0% EPS growth last quarter, while sales growth came in at -55%.
The company holds the No. 112 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
